Clinical utility of β-blockers for primary and secondary prevention of coronary artery disease

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 3, 2013, Pages 289-291

  Calhoun, McKenzie ^a   Cross, L Brian ^a   Cooper Dehoff, Rhonda M ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

blocker; coronary artery disease; primary prevention; secondary prevention

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84874921005     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.16     Document Type: Review

References (13)

1. Bangalore S, Steg PG, Deedwania P et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13), 1340-1349 (2012).
2. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 339(8), 489-497 (1998).
3. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Management of stable ischemic heart disease: Summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann. Intern. Med. 157(10), 735-743 (2012).
4. Carlberg B, Samuelsson O, Lindholm LH Atenolol in hypertension: Is it a wise choice? Lancet 364(9446), 1684-1689 (2004).
5. Meine TJ, Roe MT, Chen AY et al.; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. Am. Heart J. 149(6), 1622-1623 (2005).
6. Ohman EM, Bhatt DL, Steg PG et al.; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am. Heart J. 151(4), 786.e1-786.10 (2006).
7. Smith SC Jr, Benjamin EJ, Bonow RO et al.; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22), 2458-2473 (2011).
8. Krumholz HM, Anderson JL, Bachelder BL et al.; American College of Cardiology/American Heart Association Task Force on Performance Measures; American Academy of Family Physicians; American College of Emergency Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Cardiovascular Angiography and Interventions; Society of Hospital Medicine. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in collaboration with the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J. Am. Coll. Cardiol. 52(24), 2046-2099 (2008).
9. Chen ZM, Pan HC, Chen YP et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366(9497), 1622-1632 (2005).
10. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilYTrandolapril Study (INVEST): A randomized controlled trial. JAMA 290(21), 2805-2816 (2003).
11. Dahlof B, Devereux BB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359(9311), 955-1003 (2002).
12. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007).
13. Daskalopoulou SS, Khan NA, Quinn RR et al.; Canadian Hypertension Education Program. The 2012 Canadian hypertension education program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk, and therapy. Can. J. Cardiol. 28(3), 270-287 (2012).